Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sitaxentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.77 |
| ▸ | EDNRB known ✓ | P24530 | 18/20 | 0.77 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | PDE4A | P27815 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitaxentan SCHEMBL12933827 | 0.96 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933802 | 0.96 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933798 | 0.95 | EDNRA (0.77) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933796 | 0.95 | EDNRA (0.85) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933745 | 0.93 | EDNRA (0.89) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933826 | 0.93 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933814 | 0.93 | EDNRA (0.66) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933824 | 0.91 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933801 | 0.91 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933822 | 0.91 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280086-A1 | SUBSTITUTED THIOPHENES | EDNRB, ECE1, EDNRA | EDNRA 3/4885EDNRB 1/4885ABCC3 683/4885 |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | EDNRA, EDNRB, TBXA2R | EDNRA 1/4885EDNRB 2/4885ABCC3 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.